science

Tarlatamab

Tarlatamab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tarlatamab rather than just read about it. In short: Tarlatamab, sold under the brand name Imdelltra among others, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.

Key takeaways

Tarlatamab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tarlatamab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tarlatamab from memory before moving on to harder problems.

Reference excerpt

Tarlatamab, sold under the brand name Imdelltra among others, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3. The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea. Tarlatamab was approved for medical use in the United States in May 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Tarlatamab is indicated for the treatment of adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.

Adverse effects The US prescribing information for tarlatamab includes a boxed warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, as well as warnings and precautions for cytopenias, infections, hepatotoxicity, hypersensitivity, and embryo-fetal toxicity. The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea. The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium.

History Efficacy was evaluated in 99 participants with relapsed/refractory extensive stage small cell lung cancer with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study. Participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded. Participants received tarlatamab until disease progression or unacceptable toxicity. The US Food and Drug Administration (FDA) granted the application for tarlatamab priority review, breakthrough therapy, and orphan drug designations. Efficacy was evaluated in DeLLphi-304 (NCT05740566), a multi-center, randomized, open-label trial in people with small cell lung cancer with disease progression following treatment with platinum-based chemotherapy with or without an anti-PD-(L)1 antibody. In DeLLphi-304, 509 participants were randomized (1:1) to receive either tarlatamab-dlle or the investigator's choice of standard of care chemotherapy (topotecan, lurbinectedin, or amrubicin) until disease progression or unacceptable toxicity. In November 2025, the FDA granted traditional approval to tarlatamab for adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Tarlatamab received accelerated approval for this indication in 2024.

Society and culture

Legal status Tarlatamab was approved for medical use in the United States in May 2024.

Names Tarlatamab is the international nonproprietary name and the United States Adopted Name. Tarlatamab is sold under the brand name Imdelltra.

References

Further reading Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. (October 2023). "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer". The New England Journal of Medicine. 389 (22): 2063–2075. doi:10.1056/NEJMoa2307980. PMID 37861218. Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. (June 2023). "Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study". Journal of Clinical Oncology. 41 (16): 2893–2903. doi:10.1200/JCO.22.02823. PMC 10414718. PMID 36689692.

External links "Tarlatamab". NCI Drug Dictionary. "Tarlatamab (Code C175858)". NCI Thesaurus. Archived from the original on 14 February 2024. Clinical trial number NCT05060016 for "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Tarlatamab

Start with the simplest possible case. Write down what Tarlatamab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tarlatamab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tarlatamab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tarlatamab

In research: Tarlatamab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tarlatamab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tarlatamab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Lung cancer, Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Tarlatamab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tarlatamab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tarlatamab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tarlatamab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tarlatamab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tarlatamab in simple terms?

Why does Tarlatamab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tarlatamab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tarlatamab.